Interleukin-6 Dynamics in Host Immune Response: A Cross-Species Study in Humans and Camels During Coronavirus Infections
DOI:
https://doi.org/10.31185/wjps.825Keywords:
Cytokines, Interleukin-6 (IL-6), Inflammation, Immune response, Pro-inflammatory cytokinesAbstract
This study investigates the role of interleukin-6 (IL-6) as a key pro-inflammatory cytokine in coronavirus-infected humans and camels. A total of 75 serum samples from each species were analyzed using ELISA. The results revealed a significant elevation of IL-6 levels in infected individuals compared to controls (P<0.0001), indicating a strong inflammatory response. Notably, this is the first study to quantify IL-6 protein levels in dromedary camels during natural coronavirus infection, addressing a gap in camel immunology. The findings underscore IL-6 as a critical biomarker of inflammation across species. Further research is warranted to explore its mechanistic role in disease severity.
References
[1] A. H. Abbas et al., “A multidisciplinary review of long COVID to address the challenges in diagnosis and updated management guidelines,” Annals of Medicine & Surgery, vol. 87, no. 4, pp. 2105–2117, Apr. 2025, doi: 10.1097/MS9.0000000000003066. DOI: https://doi.org/10.1097/MS9.0000000000003066
[2] A. M. Ashraf, M. Y. Al-Maqtoofi, and A. A. Burghal, “COVID-19 story: Entry and immune response,” Vacunas (English Edition), vol. 26, no. 1, p. 100380, Jan. 2025, doi: 10.1016/j.vacune.2025.100380. DOI: https://doi.org/10.1016/j.vacune.2025.100380
[3] M. Subkhan et al., “Low platelet counts and monocytosis were associated with reduced risk of severe COVID-19 manifestation: a single-center study from Indonesia,” Immunopathologia Persa, vol. 11, p. e40595, Jan. 2025, doi: 10.34172/ipp.2025.40595. DOI: https://doi.org/10.34172/ipp.2025.40595
[4] H. Hasegawa, I. Mizoguchi, Y. Chiba, M. Ohashi, M. Xu, and T. Yoshimoto, “Expanding Diversity in Molecular Structures and Functions of the IL-6/IL-12 Heterodimeric Cytokine Family,” Front Immunol, vol. 7, Nov. 2016, doi: 10.3389/fimmu.2016.00479. DOI: https://doi.org/10.3389/fimmu.2016.00479
[5] K. Suzuki, “Cytokine Response to Exercise and Its Modulation,” Antioxidants, vol. 7, no. 1, p. 17, Jan. 2018, doi: 10.3390/antiox7010017. DOI: https://doi.org/10.3390/antiox7010017
[6] A. Y. Majeed, N. E. S. Zulkafli, and A. H. Ad’hiah, “Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection.,” Immunol Lett, vol. 260, pp. 24–34, Aug. 2023, doi: 10.1016/j.imlet.2023.06.008. DOI: https://doi.org/10.1016/j.imlet.2023.06.008
[7] S. C. Jordan et al., “Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection,” Transplantation, vol. 101, no. 1, pp. 32–44, Jan. 2017, doi: 10.1097/TP.0000000000001452. DOI: https://doi.org/10.1097/TP.0000000000001452
[8] T. Tanaka, M. Narazaki, and T. Kishimoto, “IL-6 in Inflammation, Immunity, and Disease,” Cold Spring Harb Perspect Biol, vol. 6, no. 10, pp. a016295–a016295, Oct. 2014, doi: 10.1101/cshperspect.a016295. DOI: https://doi.org/10.1101/cshperspect.a016295
[9] T. Kishimoto and K. Ishizaka, “Regulation of Antibody Response in Vitro,” The Journal of Immunology, vol. 116, no. 2, pp. 534–541, Feb. 1976, doi: 10.4049/jimmunol.116.2.534. DOI: https://doi.org/10.4049/jimmunol.116.2.534
[10] J. Scheller, C. Garbers, and S. Rose-John, “Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities,” Semin Immunol, vol. 26, no. 1, pp. 2–12, Feb. 2014, doi: 10.1016/j.smim.2013.11.002. DOI: https://doi.org/10.1016/j.smim.2013.11.002
[11] C. A. Hunter and S. A. Jones, “IL-6 as a keystone cytokine in health and disease,” Nat Immunol, vol. 16, no. 5, pp. 448–457, May 2015, doi: 10.1038/ni.3153. DOI: https://doi.org/10.1038/ni.3153
[12] Y. Takeshita et al., “New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD,” Neurol Neuroimmunol Neuroinflamm, vol. 8, no. 6, Nov. 2021, doi: 10.1212/NXI.0000000000001076. DOI: https://doi.org/10.1212/NXI.0000000000001076
[13] H. A. M. Wols, G. H. Underhill, G. S. Kansas, and P. L. Witte, “The Role of Bone Marrow-Derived Stromal Cells in the Maintenance of Plasma Cell Longevity,” The Journal of Immunology, vol. 169, no. 8, pp. 4213–4221, Oct. 2002, doi: 10.4049/jimmunol.169.8.4213. DOI: https://doi.org/10.4049/jimmunol.169.8.4213
[14] G. Tosato et al., “Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6),” Science (1979), vol. 239, no. 4839, pp. 502–504, Jan. 1988, doi: 10.1126/science.239.4839.502. DOI: https://doi.org/10.1126/science.239.4839.502
[15] I. Madhloom, R. Othman, and H. Al-bayati, “Molecular detection of coronavirus in camelids and bovines using real-time quantitative polymerase chain reaction in Wasit Province, Iraq” Open Vet J, no. 0, p. 1, 2025, doi: 10.5455/OVJ.2025.v15.i2.25. DOI: https://doi.org/10.5455/OVJ.2025.v15.i2.25
[16] A. Raheem Hashim, H. Ala Farid, Z. Adil, N. Haikaz Hasrat, Z. Adil Yakob, and Y. Ala Sabeeh, “The occurrence of cytokine storm syndrome among ICU patients with covid-19 in Basrah city, southern of Iraq: Does Tocilizumab affect the outcome?”, doi: 10.37896/sr8.7/013.
[17] W. Hafez et al., “Interleukin-6 and the determinants of severe COVID-19: A retrospective cohort study.,” Medicine, vol. 102, no. 45, p. e36037, Nov. 2023, doi: 10.1097/MD.0000000000036037. DOI: https://doi.org/10.1097/MD.0000000000036037
[18] J. X. Yin et al., “Increased interleukin-6 is associated with long COVID-19: a systematic review and meta-analysis,” Infect Dis Poverty, vol. 12, no. 1, p. 43, Apr. 2023, doi: 10.1186/s40249-023-01086-z. DOI: https://doi.org/10.1186/s40249-023-01086-z
[19] E. A. Said et al., “Defining IL‐6 levels in healthy individuals: A meta‐analysis,” J Med Virol, vol. 93, no. 6, pp. 3915–3924, Jun. 2021, doi: 10.1002/jmv.26654. DOI: https://doi.org/10.1002/jmv.26654
[20] S. Hara et al., “Comparison of the levels of neopterin, CRP, and IL-6 in patients infected with and without SARS-CoV-2,” Heliyon, vol. 8, no. 5, p. e09371, May 2022, doi: 10.1016/j.heliyon.2022.e09371. DOI: https://doi.org/10.1016/j.heliyon.2022.e09371
[21] S. Mollazadeh et al., “Investigation of IL-6 serum level in COVID-19 patients with positive COVID-19 IgG/IgM antibody titers to check inflammation and disease progression,” Cytokine, vol. 177, p. 156564, May 2024, doi: 10.1016/j.cyto.2024.156564. DOI: https://doi.org/10.1016/j.cyto.2024.156564
[22] R. S. Rasheed and S. Salim, “Interleukin 6 Levels and their Correlation with Various Hematological and Biochemical Parameters in Covid-19 Patients,” AL-Kindy College Medical Journal, vol. 19, no. 1, pp. 75–80, Apr. 2023, doi: 10.47723/kcmj.v19i1.893. DOI: https://doi.org/10.47723/kcmj.v19i1.893
[23] M. Pal, M. A. Febbraio, and M. Whitham, “From cytokine to myokine: the emerging role of interleukin‐6 in metabolic regulation,” Immunol Cell Biol, vol. 92, no. 4, pp. 331–339, Apr. 2014, doi: 10.1038/icb.2014.16. DOI: https://doi.org/10.1038/icb.2014.16
[24] H. T. Thwiny, T. A. Al Hamed, and A. R. Nazzal, “Seroepidemiological study of Middle East Respiratory Syndrome (MERS) virus infection in Iraqi dromedary camels,” Vet Arh, vol. 88, no. 2, pp. 191–200, Mar. 2018, doi: 10.24099/vet.arhiv.161224. DOI: https://doi.org/10.24099/vet.arhiv.161224
[25] M. El-Boshy, H. Abbas, S. El-Khodery, and S. Osman, “Cytokine response and clinicopathological findings in Brucella infected camels (Camelus dromedarius),” Vet Med (Praha), vol. 54, no. 1, pp. 25–32, Jan. 2009, doi: 10.17221/3044-VETMED. DOI: https://doi.org/10.17221/3044-VETMED
[26] X. Yu, Y. Wu, J. Zhang, Jirimutu, A. Zulipikaer, and J. Chen, “Pre-evaluation of humoral immune response of Bactrian camels by the quantification of Th2 cytokines using real-time PCR,” The Journal of Biomedical Research, vol. 34, no. 5, p. 387, 2020, doi: 10.7555/JBR.34.20190035. DOI: https://doi.org/10.7555/JBR.34.20190035
[27] J. Hussen and H. J. Schuberth, “Recent Advances in Camel Immunology,” Front Immunol, vol. 11, Jan. 2021, doi: 10.3389/fimmu.2020.614150. DOI: https://doi.org/10.3389/fimmu.2020.614150
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ibrahim Hasan, Hussein A. Mohamed, Rasha M. Othman
This work is licensed under a Creative Commons Attribution 4.0 International License.
